Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) Director Carl Gordon acquired 30,722 shares of the firm’s stock in a transaction dated Friday, May 13th. The shares were purchased at an average price of $2.49 per share, for a total transaction of $76,497.78. Following the completion of the transaction, the director now directly owns 14,817,994 shares in the company, valued at $36,896,805.06. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of NASDAQ:CMPX traded down $0.01 on Wednesday, reaching $2.44. The company’s stock had a trading volume of 342 shares, compared to its average volume of 267,686. Compass Therapeutics, Inc. has a 52-week low of $1.25 and a 52-week high of $5.92. The company has a 50-day simple moving average of $1.58 and a 200 day simple moving average of $2.09.
Compass Therapeutics (NASDAQ:CMPX – Get Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.07. On average, analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in the stock. Difesa Capital Management LP acquired a new stake in Compass Therapeutics in the fourth quarter valued at approximately $33,000. Monashee Investment Management LLC acquired a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $6,340,000. Qube Research & Technologies Ltd acquired a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $92,000. New Capital Management LP acquired a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $77,000. Finally, CM Management LLC acquired a new stake in shares of Compass Therapeutics in the first quarter worth approximately $411,000. Institutional investors own 66.04% of the company’s stock.
About Compass Therapeutics (Get Rating)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area.
- Get a free copy of the StockNews.com research report on Compass Therapeutics (CMPX)
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
- Dynatrace: Fundamentals are Positive While Being Punished
- Now’s The Time To Buy Disney (NYSE: DIS)
- Target Follows Walmart Lower In A Downward Spiral Of Inflation
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.